406 related articles for article (PubMed ID: 21510839)
1. Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein.
Chen SJ; Jiaang WT
Curr Top Med Chem; 2011; 11(12):1447-63. PubMed ID: 21510839
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.
Lankas GR; Leiting B; Roy RS; Eiermann GJ; Beconi MG; Biftu T; Chan CC; Edmondson S; Feeney WP; He H; Ippolito DE; Kim D; Lyons KA; Ok HO; Patel RA; Petrov AN; Pryor KA; Qian X; Reigle L; Woods A; Wu JK; Zaller D; Zhang X; Zhu L; Weber AE; Thornberry NA
Diabetes; 2005 Oct; 54(10):2988-94. PubMed ID: 16186403
[TBL] [Abstract][Full Text] [Related]
3. Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein.
Tsai TY; Yeh TK; Chen X; Hsu T; Jao YC; Huang CH; Song JS; Huang YC; Chien CH; Chiu JH; Yen SC; Tang HK; Chao YS; Jiaang WT
J Med Chem; 2010 Sep; 53(18):6572-83. PubMed ID: 20718420
[TBL] [Abstract][Full Text] [Related]
4. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
Kirby M; Yu DM; O'Connor S; Gorrell MD
Clin Sci (Lond); 2009 Sep; 118(1):31-41. PubMed ID: 19780719
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.
Someya Y; Tahara A; Nakano R; Matsuyama-Yokono A; Nagase I; Fukunaga Y; Takasu T; Hayakawa M; Shibasaki M
Naunyn Schmiedebergs Arch Pharmacol; 2008 May; 377(3):209-17. PubMed ID: 18398600
[TBL] [Abstract][Full Text] [Related]
6. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
Havale SH; Pal M
Bioorg Med Chem; 2009 Mar; 17(5):1783-802. PubMed ID: 19217790
[TBL] [Abstract][Full Text] [Related]
7. Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery.
Van der Veken P; Haemers A; Augustyns K
Curr Top Med Chem; 2007; 7(6):621-35. PubMed ID: 17352682
[TBL] [Abstract][Full Text] [Related]
8. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.
Singh AK; Jatwa R; Purohit A; Ram H
J Asian Nat Prod Res; 2017 Oct; 19(10):1036-1045. PubMed ID: 28351157
[TBL] [Abstract][Full Text] [Related]
9. Enhancing incretin action for the treatment of type 2 diabetes.
Drucker DJ
Diabetes Care; 2003 Oct; 26(10):2929-40. PubMed ID: 14514604
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.
Ahrén B; Schmitz O
Horm Metab Res; 2004; 36(11-12):867-76. PubMed ID: 15655721
[TBL] [Abstract][Full Text] [Related]
11. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
12. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
Thomas L; Eckhardt M; Langkopf E; Tadayyon M; Himmelsbach F; Mark M
J Pharmacol Exp Ther; 2008 Apr; 325(1):175-82. PubMed ID: 18223196
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
Mentlein R; Gallwitz B; Schmidt WE
Eur J Biochem; 1993 Jun; 214(3):829-35. PubMed ID: 8100523
[TBL] [Abstract][Full Text] [Related]
14. Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas.
Stremenová J; Mares V; Lisá V; Hilser M; Krepela E; Vanicková Z; Syrucek M; Soula O; Sedo A
Int J Oncol; 2010 Feb; 36(2):351-8. PubMed ID: 20043068
[TBL] [Abstract][Full Text] [Related]
15. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?
Deacon CF; Ahrén B; Holst JJ
Expert Opin Investig Drugs; 2004 Sep; 13(9):1091-102. PubMed ID: 15330741
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
Mest HJ; Mentlein R
Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466
[TBL] [Abstract][Full Text] [Related]
18. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
Green BD; Gault VA; O'harte FP; Flatt PR
Curr Pharm Des; 2004; 10(29):3651-62. PubMed ID: 15579061
[TBL] [Abstract][Full Text] [Related]
19. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
[TBL] [Abstract][Full Text] [Related]
20. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
